Reports world wide Gastrointestinal Stromal Tumor (GIST)

Market Spotlight: Gastrointestinal Stromal Tumor (GIST)
This Market Spotlight report covers the gastrointestinal stromal tumor (GIST) market,
comprising key pipeline and marketed drugs, clinical trials, key regulatory events, patent
information, a 10-year disease prevalence forecast, and drug-specific revenue forecasts.
Key Takeaways
Datamonitor Healthcare estimates that In 2016, there were 96,400 incident cases of
gastrointestinal stromal tumor (GIST) worldwide, and expects that number to increase to
105,600 incident cases by 2025.
Incidence is highest in Asia and lowest in Northern America. The approved drugs in the
GIST space target platelet-derived growth factor receptor (PDGFR), BCR-ABL fusion protein,
vascular endothelial growth factor (VEGF) receptor, KIT/c-KIT, Raf kinase, and FMS-like
tyrosine kinase 3. All the marketed drugs for GIST are administered via the oral route.
The majority of industry-sponsored drugs in active clinical development for GIST are in
Phase II, with only two drugs in Phase III. Therapies in mid- to late-stage development for
GIST focus on a variety of targets. The majority of pipeline drugs in mid- to latestage
development for GIST are administered via the oral route.
Sutent’s (sunitinib) US method of use patent is set to expire in December 2020, which will
open the door to generic entry.
Gleevec (imatinib) sales ranked highest in the GIST space during 2012–16. The clinical trials
distribution across Phases I–IV indicates that the majority of trials for GIST have been in
early and mid-phases of development, with 83% of trials in Phase I–II and only 17% in
Phase III–IV.
The US has a substantial lead in the number of GIST clinical trials globally. The UK leads the
major EU markets, while Japan has the top spot in Asia.
Clinical trial activity in the GIST space is dominated by completed trials. Novartis and Pfizer
have the highest number of completed clinical trials for this condition, with 55 and 30,
respectively. Novartis leads industry sponsors with the highest number of clinical trials for
GIST
Exclusive Sample Report @
Major TOC Market:
KEY TAKEAWAYS
DISEASE BACKGROUND
TREATMENT
Surgery
Targeted therapy
Other treatments
https://www.reportsworldwide.com/enquiry?report_id=42614